Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of the combination of
biweekly docetaxel and bevacizumab in the first line treatment of metastatic breast cancer by
using Response Evaluation Criteria In Solid Tumors (RECIST criteria) and NCI Common
Terminology Criteria for Adverse Events (NCI CTC-AE) version 3. In addition several
biochemical makers are tested as possible predictive factors.
Phase:
Phase 2
Details
Lead Sponsor:
Tampere University Hospital
Collaborators:
Oulu University Hospital Turku University Hospital